Overview

Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF Lenvatinib As First-line Treatment for Advanced ICC

Status:
NOT_YET_RECRUITING

Trial end date:
2028-04-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open label, randomized, two-arm clinical study to observe and evaluate the efficacy and safety of adebrelimab combined with irinotecan liposomes, 5-fluorouracil, calcium folinate lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma (ICC).

Phase:

PHASE2

Details

Lead Sponsor:

Harbin Medical University

Treatments:

Fluorouracil
lenvatinib
Leucovorin